MMV will receive £25 million towards the hunt for innovative new medicines for malaria
DFID has pledged £138 million until 2018 to nine product development partnerships, including £25 million for MMV, for the development of new tools to treat, control and ultimately eliminate some of the world’s deadliest diseases.
The UK government’s commitment to combating diseases that place an enormous burden on the world’s poor, is commendable.
International Development Secretary, Justine Greening, said, “Working together in product development partnerships, the public and private sectors have a chance to bring together their expertise for the benefit of millions of the world’s poorest and most vulnerable people.”
DFID was central to the creation of MMV in 1999, contributing to the initial $4 million that launched MMV’s discovery, development and delivery efforts for new medicines for malaria. Since then, it has been a consistent and generous supporter of MMV’s work for 13 years, providing 15% of our entire funding since foundation.
“DFID has been a long-term supporter of MMV’s work and we are honoured to be included as a recipient for continued support from the UK government,” said Dr David Reddy, CEO of MMV. “This will give us the stimulus to continue to develop and deliver new antimalarials for a broader population, including groups that are disproportionately affected by this terrible disease, e.g., pregnant women and children. It will also help us develop drugs that will target both major strains of malaria, P.falciparum and P.vivax, and ultimately contribute towards the elimination and eradication of malaria.”
In addition to the sustained funding we receive from our other donors, DFID’s support has been critical to our success over the past 13 years, allowing MMV and partners to bring forward four new antimalarials from 2009 to 2012: Pyramax®, (pyronaridine-artesunate) co-developed with Shin Poong; Eurartesim® (dihydroartemisinin-piperaquine) with Sigma-Tau; Guilin’s artesunate injection for the treatment of severe malaria, Artesun®; and Coartem® Dispersible (artemether-lumefantrine), a child-friendly artemisinin-combination therapy (ACT) developed with Novartis.
Read the DFID press release.